Pharmanutra S.p.A. (BIT: PHN)

Market Cap	499.61M
Revenue (ttm)	113.13M
Net Income (ttm)	16.27M
Shares Out	9.61M
EPS (ttm)	1.69
PE Ratio	30.84
Forward PE	25.19
Dividend	0.85 (1.63%)
Ex-Dividend Date	May 6, 2024

Volume	3,712
Average Volume	3,118
Open	51.90
Previous Close	52.30
Day's Range	51.40 - 52.50
52-Week Range	44.85 - 63.50
Beta	0.34
RSI	38.05
Earnings Date	Mar 14, 2025

About Pharmanutra

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 105
• Stock Exchange: Borsa Italiana
• Ticker Symbol: PHN

Financial Performance

In 2023, Pharmanutra's revenue was 101.03 million, an increase of 21.64% compared to the previous year's 83.06 million. Earnings were 12.83 million, a decrease of -14.73%.